Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
 Advanced NanoTherapiesCompany profile Advanced NanoTherapies develops nanoparticle-coated balloons that deliver two drugs locally during vascular procedures, starting with its investigational SirPlux Duo device. Advanced NanoTherapies develops nanoparticle-coated balloons that deliver two drugs locally during vascular procedures, starting with its investigational SirPlux Duo device. | >$31M | Series B | Biotech, Healthtech | United States | Investors | |
| IB IMU BiosciencesCompany profile Profiles human immune systems using multi-omic analysis and machine learning for disease research. Profiles human immune systems using multi-omic analysis and machine learning for disease research. | $53M | Series A | Biotech | United Kingdom | Investors | |
| TB Develops novel therapeutics for glaucoma and retinal diseases | $17M | Series A | Biotech | United States | Investors | |
| C ContralineCompany profile Develops hormonal and non-hormonal male contraceptives for men and couples globally Develops hormonal and non-hormonal male contraceptives for men and couples globally | $92.5M | Series B | Biotech | United States | Investors | |
| N NovelliaCompany profile Platform that unifies patient health records for individuals and supplies anonymized data to pharma researchers Platform that unifies patient health records for individuals and supplies anonymized data to pharma researchers | $18M | Series A | Biotech, Healthtech | United States | Investors | |
 NewLimitCompany profile NewLimit develops epigenetic reprogramming medicines designed to restore function in aging cells and treat age-related disease. NewLimit develops epigenetic reprogramming medicines designed to restore function in aging cells and treat age-related disease. | $435M | Series CSeries C+ | Biotech | United States | Investors | |
| WB Waypoint BioCompany profile Develops AI-designed CAR T therapies for solid tumors using spatial biology Develops AI-designed CAR T therapies for solid tumors using spatial biology | $20M | Series A | Biotech | United States | Investors | |
| CL Develops single-molecule PCR technology for genomics measurement | $26M | Series A | Biotech | United States | Investors | |
| T TriomicsCompany profile Building AI infrastructure to turn complex cancer records into structured intelligence Building AI infrastructure to turn complex cancer records into structured intelligence | $22M | Series B | Biotech, Healthtech | United States | Investors | |
| P PsileraCompany profile Develops next-generation neuroplastogens and psychedelic therapies for neurological conditions Develops next-generation neuroplastogens and psychedelic therapies for neurological conditions | $8.8M | Seed+Seed | Biotech | United States | Investors Undisclosed |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.